Media Articles Related to Aloprim (Allopurinol)
Gout: data from Phase III studies of lesinurad in combination with allopurinol
Source: Gout News From Medical News Today [2014.11.19]
AstraZeneca has presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination...
Gout drug may reduce risk of death
Source: Gout News From Medical News Today [2014.03.26]
In a recently to be published study in Annals of the Rheumatic Diseases, researchers have found the use of the drug allopurinol was associated with a reduced risk of death in hyperuricemic (gout)...
Published Studies Related to Aloprim (Allopurinol)
In a double-blind, randomized and placebo-controlled trial, adjuvant allopurinol
improved symptoms of mania in in-patients suffering from bipolar disorder. 
Allopurinol is a drug used primarily to treat hyperuricemia. In patients
suffering from acute mania, increased levels of uric acid are observed, and
symptom improvements are associated with decreased levels of uric acid...
Allopurinol for mania: a randomized trial of allopurinol versus placebo as add-on
treatment to mood stabilizers and/or antipsychotic agents in manic patients with
bipolar disorder. 
bipolar disorder... CONCLUSIONS: The findings of this large, well-powered study do not support add-on
Allopurinol reduces left ventricular mass in patients with type 2 diabetes and
left ventricular hypertrophy. 
regression of LVH in patients with T2DM... CONCLUSIONS: Allopurinol causes regression of LVM in patients with T2DM and LVH.
High-dose allopurinol reduces left ventricular mass in patients with ischemic
heart disease. 
to reduce LV afterload in IHD and may therefore also regress LVH... CONCLUSIONS: High-dose allopurinol regresses LVH, reduces LV end-systolic volume,
Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. [2011.08.16]
OBJECTIVES: The aim of this study was to evaluate the effect of high-dose allopurinol on vascular oxidative stress (OS) and endothelial function in subjects with stable coronary artery disease (CAD). BACKGROUND: Allopurinol, a xanthine oxidase inhibitor, prolongs the time to chest pain during exercise in angina. We sought to ascertain whether allopurinol also improves endothelial dysfunction in optimally treated CAD patients, because such an effect might be of value to reduce future cardiovascular mortality. The mechanism of the anti-ischemic effect of allopurinol could be related to its reducing xanthine oxidase-induced OS, and our second aim was to see whether allopurinol really does reduce vascular tissue OS in CAD patients... CONCLUSIONS: Our study demonstrates that, in optimally treated CAD patients, high-dose allopurinol profoundly reduces vascular tissue OS and improves 3 different measures of vascular/endothelial dysfunction. The former effect on OS might underpin the anti-ischemic effect of allopurinol in CAD. Both effects (on OS and endothelial dysfunction) increase the likelihood that high-dose allopurinol might reduce future cardiovascular mortality in CAD, over and above existing optimum therapy. (Exploring the therapeutic potential of xanthine oxidase inhibitor allopurinol in angina; ISRCTN15253766). Copyright (c) 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Clinical Trials Related to Aloprim (Allopurinol)
A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL [Recruiting]
This research is being done to determine if allopurinol can change the metabolism of the
oral chemotherapeutic medication 6-mercaptopurine (6-MP) in children with acute
lymphoblastic leukemia (ALL). 6-MP is originally started at a standard dose in children with
ALL, but the dose is adjusted according to the absolute neutrophil count (ANC).
Occasionally, 6-MP doses need to be increased in order to get the ANC into a specific target
range. Also, increasing the 6-MP dose can lead to unwanted side effects, such as
inflammation of the liver as shown by increases in laboratory values (ALT, aspartate
aminotransferase (AST), bilirubin), nausea, and abdominal discomfort. Previous studies in
children with inflammatory bowel disease has shown that combining allopurinol with 6-MP can
decrease side effects associated with high doses of 6-MP and also increase the efficacy of
6-MP. Allopurinol is approved by the Food and Drug Administration for the treatment of tumor
lysis syndrome in ALL. Through this research study, we hope to show that the combination of
allopurinol and 6-MP will be safe, tolerable, and effective in children with ALL.
Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study [Active, not recruiting]
Kidney patients on dialysis commonly die because of heart disease. One of the biggest
problems in their hearts is that the muscle wall of the heart thickens. This makes it less
efficient. We found in patients with mild kidney disease that a drug normally used to treat
gout (allopurinol) had the remarkable side effect of being able to reduce this thickening of
their heart wall. In this new study we aim to find out if this benefit of allopurinol also
occurs in severe kidney patients i. e. those on regular dialysis. We also are trying to
figure out the best dose of allopurinol to use. To do this we are planning a study where we
will recruit patients with kidney disease who are on dialysis. The 1st phase of the trial
will be to determine the best dose of allopurinol to use and the second phase will be to do
a clinical trial where patients will be randomly allocated to either this optimum dose of
allopurinol or a dummy medication (placebo) and will receive one year of treatment. They
will have a special scan of the heart using an MRI machine to measure the extent of
thickening of their heart muscle before they start on treatment and will have a further MRI
scan when their one year treatment finishes.
Phase 1- the dose finding study, will involve 10 patients who will have between 3 and 7
visits to the hospital scheduled around 4 to 17 dialysis sessions. The later study will
involve up to 76 patients who will be asked to attend the hospital up to 8 times over a 13
Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension? [Recruiting]
Does Allopurinol regress Left Ventricular Hypertrophy in Patients with Treated Essential
People with high blood pressure are at increased risk of heart complications. One of the
biggest problems is that the muscle wall of the heart thickens. The medical term for this is
Left Ventricular Hypertrophy (LVH). LVH makes the heart less efficient and patients with LVH
are at a 10 times greater risk of heart complications than those without it.
A goal of treating high blood pressure is to reduce the strain on the heart and to try to
decrease this thickening of the heart wall. However, even when blood pressure is treated and
is under control, LVH can persist, and as there are no symptoms to LVH it can go undetected.
Currently the only way to reduce LVH would be to lower blood pressure (BP) even further.
This can cause side-effects from low BP such as dizziness and nausea.
It has previously been shown that a drug allopurinol, which is usually used to treat gout
had the remarkable side effect of being able to reduce this thickening of the heart wall in
patients who had kidney disease or diabetes. The aim now is to see if patients with high
blood pressure and LVH may also benefit from treatment with allopurinol. If LVH can be
reduced using allopurinol, this might be a new way to reduce cardiac risk in these patients
without needing to lower BP even further.
In this study the aim is to recruit 66 patients who have treated and well controlled blood
pressure but may still have LVH. They will be screened for LVH by doing an ultrasound scan
of the heart and then that will be confirmed with a Magnetic Resonance Imaging (MRI) scan,
which is a special scan of the heart using an MRI machine to measure the extent of
thickening of the heart muscle before they start on treatment of allopurinol or placebo.
As this is a clinical trial the participants will be randomly allocated to either
allopurinol or a dummy medication (placebo) and will receive one year of treatment so that
the investigators can compare if there is a difference between normal treatment and addition
of allopurinol. All the patients currently prescribed medication for their high blood
pressure will continue as normal on that. They will have a further MRI scan when their one
year treatment with allopurinol or placebo finishes.
Benefits - You will be monitored closely during the study and will be seen by a doctor with
a special interest in cardiology at each of your study visits and your medication will be
reviewed on a regular basis. The tests will give us information about the function of your
heart, kidneys and blood circulation. If any of these investigations, including information
from the MRI scan of your heart reveal any new abnormality we will either discuss this with
your hospital consultant or refer you to a specialist clinic (whichever seems most
appropriate). The study will not immediately benefit you, but if the results of the study
are positive it may change the practice of managing patients with treated high blood
pressure but may still have LVH, like you and potentially will have a great impact on other
such patients in the future. If so, you may gain eventually from our discovering a new
treatment for your condition.
Risks - The side effects of the allopurinol are very rare (less than 1 in 10,000 people) and
include headache, stomach upset, drowsiness and anaemia. Having blood tests taken can cause
some mild bruising. The flow mediated dilatation may cause temporary numbness. MRI scanning
is very safe and does not use radiation but some may feel a bit closed in. The scanner is a
bit noisy but you will be given ear protection which also plays music. Your kidney function
will be assessed before the scan to ensure it is safe to give you the contrast agent
Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia [Completed]
This is a randomized, double-blind, 3-period 3-treatment crossover followed by a 2-period
2-treatment crossover, phase 2 study in patients with documented hyperuricemia to evaluate
the effect of tranilast on allopurinol pharmacokinetics (PK) and pharmacodynamics (PD) and
to evaluate the effect of allopurinol on tranilast PK and PD as measured by reduction in
serum uric acid levels.
Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode [Completed]
The objective of the study is to evaluate the efficacy of allopurinol, compared to placebo,
as add-on to mood stabilizers and/or antipsychotic in the treatment of patients with bipolar
disorder, in a manic episode.